ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-21 08:00 |
Abivax obtient un financement maximum de 150 millions d’euros dans le cadre de …
|
French | 452.7 KB | ||
| 2023-08-21 08:00 |
Abivax secures up to EUR 150M from two structured debt financing transactions
|
English | 38.1 KB | ||
| 2023-08-10 18:00 |
Abivax annonce son intention de proceder a une offre au public aux Etats-Unis
|
French | 134.5 KB | ||
| 2023-08-10 18:00 |
Abivax announces plans to conduct registered public offering in the United Stat…
|
English | 3.9 KB | ||
| 2023-08-02 18:00 |
ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND…
|
English | 223.6 KB | ||
| 2023-08-02 18:00 |
ABIVAX: AVIS AUX PORTEURS D’OBLIGATIONS CONVERTIBLES/ECHANGEABLES EN ACTIONS NO…
|
French | 196.6 KB | ||
| 2023-07-28 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 248.1 KB | ||
| 2023-07-28 18:00 |
ABIVAX: Bilan semestriel du contrat de liquidité au 30 juin 2023.
|
French | 365.5 KB | ||
| 2023-07-11 18:00 |
Dr June Lee et Troy Ignelzi sont nommés Membres du Conseil d’administration d’A…
|
French | 229.1 KB | ||
| 2023-07-11 18:00 |
Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members …
|
English | 16.1 KB | ||
| 2023-06-22 17:31 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 248.2 KB | ||
| 2023-06-15 22:43 |
Abivax reçoit le « Capital Market Transaction of the Year Award » aux European …
|
French | 203.1 KB | ||
| 2023-06-15 22:41 |
Abivax receives Capital Market Transaction of the Year Award at the European Me…
|
English | 9.2 KB | ||
| 2023-06-09 00:19 |
Abivax annonce les résultats de son Assemblée générale ordinaire annuelle et ex…
|
French | 156.2 KB | ||
| 2023-06-08 18:00 |
ABIVAX: L’action Abivax intégrée dans les Indices MSCI
|
French | 182.6 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
